Family Medicine Doctors in Wilmington, VT Accepting Medicare
2 Family Medicine doctors found. Showing 1 - 2
 Robert H Tarnas, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 30 Vt Route 100 S, Wilmington, VT 05363 Phone: 802-464-5311 Fax: 802-464-7480 |
 Dagmar Tobits, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Vt Route 100 S, Wilmington, VT 05363 Phone: 802-464-5311 |
News Archive
Largest long-term examination of children's health and development in the US
The National Children's Study (NCS) has begun inviting women in San Diego to participate in the largest long-term examination of children's health and development ever conducted in the United States.
Air pollution exposure during fetal life related to brain abnormalities, cognitive impairment in children
A new study performed in the Netherlands has linked exposure to residential air pollution during fetal life with brain abnormalities that may contribute to impaired cognitive function in school-age children. The study, published in Biological Psychiatry, reports that the air pollution levels related to brain alterations were below those considered to be safe.
Genta reports combined data from Genasense Phase 3 trials for advanced melanoma
Genta Incorporated announced today the presentation of combined data on early endpoints from the Company's randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The presentation included a "pooled analysis" that assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. The data were presented today at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.
FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
› Verified 7 days ago